share_log

Piper Sandler Maintains Neutral on OncoCyte, Lowers Price Target to $3

Benzinga ·  Nov 13, 2023 16:18

Piper Sandler analyst David Westenberg maintains OncoCyte (NASDAQ:OCX) with a Neutral and lowers the price target from $3.5 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment